11 research outputs found
PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)
Get PDFBoceprevir Use in France: A Markov Model of Disease Progression and Cost-Effectiveness for Chronic Hepatitis C (Virus G1)
No full textPIN33 COST-UTILITY ANALYSIS OF RALTEGRAVIR IN HIV-INFECTED TREATMENT NAïVE PATIENTS IN SWEDEN
No full textPIN40 Cost-Effectiveness of Boceprevir-Based Treatment of Chronic Genotype 1 Hepatitis C Virus (HCV) Infection From the Perspective of the German Statutory Health Insurance (SHI)
No full textCost-Effectiveness Analysis of Raltegravir in Hiv-Infected Treatment Naive Patients in Greece
No full textAdding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand
No full textPIN76 Adding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand
Get PDFEconomic evaluation of innovative technologies in health care should include a short-run perspective.
Get PDFContains fulltext :
70475.pdf (publisher's version ) (Closed access)Knowledge about the cost-effectiveness of innovative technologies or new guidelines in health care is more and more a necessary condition for implementation in common practice. However, there are situations where implementation of a new technology that is found more effective and cost effective and is strongly advocated by the medical profession stagnates. The reason for this is the discrepancy between long-run efficiency, on which cost effectiveness is based, and short-run efficiency. This paper addresses the potential paradox between long-run and short-run efficiency in health care and explores possibilities to overcome hurdles to implementation due to that paradox
